Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Idexx Laboratories (IDXX)
NASDAQ:IDXX
Holding IDXX?
Track your performance easily
IDXX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$398.50 - $583.39
Previous CloseN/A
Volume277.29K
Average Volume (3M)534.07K
Market Cap
$35.65B
Enterprise Value$42.65B
Total Cash (Recent Filing)$391.85M
Total Debt (Recent Filing)$593.11M
Price to Earnings (P/E)42.0
Beta1.40
Next Earnings
Feb 03, 2025EPS Estimate
2.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.36
Shares Outstanding81,884,670
10 Day Avg. Volume581,075
30 Day Avg. Volume534,070
Standard Deviation0.10
R-Squared0.50
Alpha-0.00271
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.27
Price to Cash Flow (P/CF)40.50
P/FCF Ratio46.40
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue11.09
Enterprise Value/Gross Profit19.48
Enterprise Value/Ebitda44.54
Forecast
1Y Price Target
$484.33Price Target Upside14.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Idexx Laboratories News
PremiumCompany Announcements
Idexx Laboratories Approves Nonqualified Deferred Compensation Plan
PremiumCompany Announcements
IDEXX Laboratories Announces CFO Transition PlanBulls Say, Bears Say
Bulls Say
Market PositionIDEXX's strong market position is further reinforced by its premium valuation over peers, attributed to its historical EPS growth and strong competitive positioning in the animal diagnostics industry.
Product InnovationThe anticipated launch of InVue Dx and the upcoming Oncology portfolio is projected to be significant growth drivers, with InVue Dx expected to contribute 1-2% to EPS growth and a $1 billion market opportunity for IDXX Cancer Dx.
Revenue GrowthIDEXX Laboratories, being the dominant player in the veterinarian testing space, has consistently shown robust growth backed by a steady increase in diagnostic testing for pets, coupled with successful new product launches.
Bears Say
Earnings OutlookForecasts for FY25 and FY26 EPS have been lowered, indicating a cautious outlook on growth potential.
Financial PerformancePersistent weakness in veterinary clinic visit trends and a challenging macro backdrop drove repeated cuts to IDXX's FY24 outlook this year.
Revenue GrowthThe updated guidance implies organic growth of only 2.9% in the fourth quarter, driven by 3.6% organic CAG recurring growth, which is the lowest trend since early 2013.
---
Ownership Overview
0.96% Insiders
26.68% Mutual Funds
0.80% Other Institutional Investors
41.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $398.50 and its highest was $583.39 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $35.65B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Feb 03, 2025 which is tomorrow.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Oct 31, 2024. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.681 by $0.119.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 2.4.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 81,884,670 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $2.8 in its last earnings report, beating expectations of $2.681. Following the earnings report the stock price went down -9.79%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Among the largest hedge funds holding Idexx Laboratories’s share is Quantum Capital Management, LLC / NJ. It holds Idexx Laboratories’s shares valued at 28M.
---
Idexx Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$484.33 (14.76% Upside)
$484.33 (14.76% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 43.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.31%
12-Months-Change
Fundamentals
Return on Equity
53.54%
Trailing 12-Months
Asset Growth
8.57%
Trailing 12-Months
Company Description
Idexx Laboratories
Maine-based IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
---
IDXX Company Deck
---
IDXX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were notable achievements in revenue growth, profit performance, and innovation, there were significant challenges in CAG Diagnostic revenue and Reference Laboratory performance due to macroeconomic pressures and sector headwinds. The updated guidance reflects caution due to these ongoing challenges.Read More>---
IDXX Revenue Breakdown
65.32% U.S.
4.82% EMEA Other
4.10% Canada
4.09% Germany
21.67% Other
---
IDXX Stock 12 Month Forecast
Average Price Target
$484.33
▲(14.76% Upside)
Technical Analysis
Best Analysts Covering IDXX
1 Year
1 Year Success Rate
13/22 ratings generated profit
1 Year Average Return
+13.13%
reiterated a buy rating 4 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +13.13% per trade.
---